Brief: Calithera Biosciences Announces First Patient Enrolled In Phase 2 Clinical Trial Of Mivavotinib In Relapsed/Refractory Non-Gcb (Abc) Diffuse Large B-Cell Lymphoma

Calithera Biosciences

23/06/2022 21:55

June 23 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA BIOSCIENCES ANNOUNCES FIRST PATIENT ENROLLED IN
PHASE
2 CLINICAL TRIAL OF MIVAVOTINIB IN RELAPSED/REFRACTORY NON-GCB
(ABC) DIFFUSE LARGE B-CELL LYMPHOMA
    * CALITHERA - STUDY WILL EVALUATE SYK INHIBITOR BOTH IN
PATIENTS
WITH WILD-TYPE DISEASE AND THOSE WITH TUMORS THAT HARBOR MYD88
OR CD79B MUTATIONS
    * CALITHERA - DATA FROM TRIAL COULD POSITION CO TO INITIATE
A
STUDY WITH REGISTRATIONAL INTENT IN BIOMARKER-SPECIFIC DLBCL
POPULATIONS

Source text for Eikon:  ID:nGNX4gJw4M 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))